Literature DB >> 20634245

Frequency and phenotype of T helper 17 cells in peripheral blood and synovial fluid of patients with reactive arthritis.

Hui Shen1, Jane C Goodall, J S Hill Gaston.   

Abstract

OBJECTIVE: To analyze the frequency and phenotype of peripheral blood mononuclear cells (PBMC) and synovial fluid mononuclear cell (SFMC) T helper (Th)17 cells in reactive arthritis (ReA).
METHODS: T cell surface phenotype and cytokine production were measured following stimulation, using 8-color flow cytometry.
RESULTS: The percentages of interleukin 17 (IL-17)-positive CD4+ T cells were increased in SFMC of patients with ReA compared with PBMC. All IL-17+ cells were CD4+CD45RO+; in SFMC most expressed CCR6, but only 50% expressed CCR4. IL-17+ cells sometimes coexpressed IL-22 and/or interferon-γ, but not IL-10.
CONCLUSION: These data support the hypothesis that Th17 cells are involved in ReA pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634245     DOI: 10.3899/jrheum.100146

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond.

Authors:  Judith A Smith; Robert A Colbert
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

Review 2.  Focal bone involvement in inflammatory arthritis: the role of IL17.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Elena Fracassi; Davide Gatti
Journal:  Rheumatol Int       Date:  2015-10-31       Impact factor: 2.631

3.  Relationship of CD146 expression to secretion of interleukin (IL)-17, IL-22 and interferon-γ by CD4(+) T cells in patients with inflammatory arthritis.

Authors:  C Wu; J C Goodall; R Busch; J S H Gaston
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

4.  Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway.

Authors:  Mengguo Liu; Ji Yang; Xiaojing Xing; Xiangxiang Cui; Ming Li
Journal:  Arthritis Res Ther       Date:  2014-12-31       Impact factor: 5.156

Review 5.  Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis.

Authors:  Annika Reinhardt; Immo Prinz
Journal:  Front Immunol       Date:  2018-04-25       Impact factor: 7.561

Review 6.  The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.

Authors:  Dennis G McGonagle; Iain B McInnes; Bruce W Kirkham; Jonathan Sherlock; Robert Moots
Journal:  Ann Rheum Dis       Date:  2019-07-05       Impact factor: 19.103

7.  Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression.

Authors:  Bina Menon; Nicola J Gullick; Gina J Walter; Megha Rajasekhar; Toby Garrood; Hayley G Evans; Leonie S Taams; Bruce W Kirkham
Journal:  Arthritis Rheumatol       Date:  2014-05       Impact factor: 10.995

8.  The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression.

Authors:  Matteo Vecellio; Amity R Roberts; Carla J Cohen; Adrian Cortes; Julian C Knight; Paul Bowness; B Paul Wordsworth
Journal:  Ann Rheum Dis       Date:  2015-10-09       Impact factor: 19.103

Review 9.  The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis.

Authors:  Hiroyuki Tsukazaki; Takashi Kaito
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

10.  Th17 and Th22 cells in psoriatic arthritis and psoriasis.

Authors:  Helen Benham; Paul Norris; Jane Goodall; Mihir D Wechalekar; Oliver FitzGerald; Agnes Szentpetery; Malcolm Smith; Ranjeny Thomas; Hill Gaston
Journal:  Arthritis Res Ther       Date:  2013-09-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.